Evommune (EVMN) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evommune is the larger company by market cap ($232.6 million vs $222.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | GLSI |
|---|---|---|
| Share price | $6.41 | $15.14 |
| Market cap | $232.63M | $222.23M |
| 1-day change | +3.05% | -1.62% |
| YTD return | -62.56% | -27.94% |
| 1-year return | — | +32.28% |
| 5-year return | — | -60.12% |
| EPS (TTM) | $-3.75 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $34.10 |
| 52-week low | $6.02 | $7.78 |
| Distance from 52-week high | -80.69% | -55.60% |
| Analyst consensus | buy | none |
| Avg. price target upside | +276.44% | +276.49% |
| Average volume | 697.98K | 138.91K |
| Shares outstanding | 36.29M | 14.68M |
| Employees | 48 | — |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Evommune in Health Care and Greenwich LifeSciences in Healthcare.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
EVMN vs GLSI FAQ
Which is bigger, Evommune or Greenwich LifeSciences?
Evommune (EVMN) is larger, with a market capitalization of $232.63M compared with $222.23M for Greenwich LifeSciences (GLSI).
Are Evommune and Greenwich LifeSciences in the same industry?
No. Evommune is in the Health Care sector, while Greenwich LifeSciences is in Healthcare.